title: Propranolol and Mesenchymal Stromal Cells Combine to Treat Traumatic Brain Injury.
abstract: More than 6.5 million patients are burdened by the physical, cognitive, and psychosocial deficits associated with traumatic brain injury (TBI) in the U.S. Despite extensive efforts to develop neuroprotective therapies for this devastating disorder, there have been no successful outcomes in human clinical trials to date. Retrospective studies have shown that β-adrenergic receptor blockers, specifically propranolol, significantly decrease mortality of TBI through mechanisms not yet fully elucidated but are thought to counterbalance a hyperadrenergic state resulting from a TBI. Conversely, cellular therapies have been shown to improve long-term behavior following TBI, likely by reducing inflammation. Given the nonredundancy in their therapeutic mechanisms, we hypothesized that a combination of acute propranolol followed by mesenchymal stem cells (MSCs) isolated from human bone marrow would have additive effects in treating a rodent model of TBI. We have found that the treatments are well-tolerated individually and in combination with no adverse events. MSCs decrease BBB permeability at 96 hours after injury, inhibit a significant accumulation of activated microglia/macrophage in the thalamic region of the brain both short and long term, and enhance neurogenesis short term. Propranolol decreases edema and reduces the number of fully activated microglia at 7 days and the number of semiactivated microglia at 120 days. Combinatory treatment improved cognitive and memory functions 120 days following TBI. Therefore, the results here suggest a new, efficacious sequential treatment for TBI may be achieved using the β-blocker propranolol followed by MSC treatment.
  
  
  CONCLUSIONS
  Despite continuous efforts, traumatic brain injury (TBI) remains the leading cause of death and disability worldwide in patients under the age of 44. In this study, an animal model of moderate-severe TBI was treated with an acute dose of propranolol followed by a delayed dose of human mesenchymal stem cells (MSCs), resulting in improved short- and long-term measurements. These results have direct translational application. They reinforce the inevitable clinical trial of MSCs to treat TBI by demonstrating, among other benefits, a notable decrease in chronic neuroinflammation. More importantly, these results demonstrate that MSCs and propranolol, which is increasingly being used clinically for TBI, are compatible treatments that improve overall outcome.
authors.affiliation: Department of Pediatric Surgery, University of Texas Health Science Center at Houston, Houston, Texas, USA.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Kota
authors.affiliation: Department of Pediatric Surgery, University of Texas Health Science Center at Houston, Houston, Texas, USA.
authors.forename: Karthik S
authors.initials: KS
authors.lastname: Prabhakara
authors.affiliation: Department of Pediatric Surgery, University of Texas Health Science Center at Houston, Houston, Texas, USA.
authors.forename: Alexandra J
authors.initials: AJ
authors.lastname: van Brummen
authors.affiliation: Department of Pediatric Surgery, University of Texas Health Science Center at Houston, Houston, Texas, USA.
authors.forename: Supinder
authors.initials: S
authors.lastname: Bedi
authors.affiliation: Department of Pediatric Surgery, University of Texas Health Science Center at Houston, Houston, Texas, USA.
authors.forename: Hasen
authors.initials: H
authors.lastname: Xue
authors.affiliation: Department of Pediatric Surgery, University of Texas Health Science Center at Houston, Houston, Texas, USA.
authors.forename: Bryan
authors.initials: B
authors.lastname: DiCarlo
authors.affiliation: Department of Pediatric Surgery, University of Texas Health Science Center at Houston, Houston, Texas, USA.
authors.forename: Charles S
authors.initials: CS
authors.lastname: Cox
authors.affiliation: Department of Pediatric Surgery, University of Texas Health Science Center at Houston, Houston, Texas, USA Scott.D.Olson@uth.tmc.edu.
authors.forename: Scott D
authors.initials: SD
authors.lastname: Olson
mesh_terms: D000328:Adult; D064591:Allografts; D000818:Animals; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D001930:Brain Injuries / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D006801:Humans; D008297:Male; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000378:metabolism* / Q000473:pathology; D017628:Microglia / Q000378:metabolism* / Q000473:pathology; D055495:Neurogenesis / Q000187:drug effects*; D011433:Propranolol / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D011433:Propranolol
keywords: Mesenchymal stromal cell; Propranolol; Traumatic brain injury; β-Blocker